Cognito Therapeutics
Company · Cambridge, Massachusetts, USA
Uses 40 Hz light and sound stimulation (gamma sensory stimulation) in trials for Alzheimer's disease.
In the news
Non-invasiveClinical trials
Cognito's Spectris misses primary endpoint in pivotal Alzheimer's trial
The 673-person HOPE study of 40 Hz light and sound stimulation did not beat sham overall; Cognito points to a pre-specified mild-disease subgroup and plans to talk to the FDA.
IndustryNon-invasive
Cognito Therapeutics and Rhode Island launch a statewide brain health collaboratory
The state's Life Science Hub will work with Cognito, Brown University and local health systems to study and deploy the company's Spectris sensory stimulation platform for Alzheimer's disease.
FundingNon-invasive
Cognito Therapeutics raises $105 million ahead of pivotal Alzheimer's results
Its Spectris headset delivers 40 Hz light and sound stimulation at home; the fully enrolled HOPE study is due to read out this year.